Solventum presently has a consensus target price of $79.86, indicating a potential upside of 7.91%. As a group, “Surgical & medical instruments” companies have a potential upside of 31.38%.

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Solventum, the 3M healthcare spinoff, eliminated 800 positions as part of a restructuring strategy to help ...

Solventum (NYSE: SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership ...

In the final days of November, I was getting slightly concerned about a long position in Solventum Corporation (NYSE:SOLV) after shares had enjoyed a partial re-rating. By now, the healthcare spin ...

MAPLEWOOD, Minn. (AP) — MAPLEWOOD, Minn. (AP) — Solventum Corp. (SOLV) on Thursday reported fourth-quarter net income of $30 million. The Maplewood, Minnesota-based company said it had net ...

Feb 27 (Reuters) - 3M spin-off Solventum (SOLV.N), opens new tab forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization ...

Solventum (SOLV) announced a strategic partnership with SprintRay, a provider of chairside 3D dental printing, to meet the needs of dentists with in-office chairside 3D printed crowns, inlays, onlays ...